Titelia

Holdings of Lynx1 Capital Management LP

20 declared positions · as of Mar 31, 2026

Original filing · Ten largest lines: 97.6 % of the equity sleeve

Sector breakdown

  • Unattributed 100.0 %

Titelia classification, company by company. The unattributed share stays visible.

Currency breakdown

  • USD 100.0 %

The quoted currency of each line, as declared.

Country breakdown

  • US 100.0 %

Shares computed on the equity sleeve.

RankCountryLinesValueShare
1US20479.1M $100.00 %

Positions

RankCompanySharesValueWeight
1Stoke Therapeutics Inc 4,763,673155.1M $
2Cullinan Therapeutics Inc 8,963,500127.4M $
3Agios Pharmaceuticals Inc 2,611,56888.3M $
4Denali Therapeutics Inc 1,880,30336.1M $
5C4 Therapeutics Inc 6,998,90218.4M $
6Korro Bio Inc 1,538,29617.4M $
7TScan Therapeutics Inc 8,019,1488.1M $
8Xencor Inc 536,3986.5M $
9Precision BioSciences Inc 985,1135.4M $
10Passage Bio Inc 623,7044.9M $
11NEUPHORIA THERAPEUTICS INC 875,3283.6M $
12Entrada Therapeutics Inc 211,6892.7M $
13CG oncology Inc 31,5912.1M $
14Design Therapeutics Inc 119,5161.3M $
15VYNE THERAPEUTICS INC 1,628,700973.1K $
16WEREWOLF THERAPEUTICS INC 657,786547.7K $
17IBIO INC 68,076129.3K $
18BOLT BIOTHERAPEUTICS INC 30,800124.4K $
19Absci Corp 21,24563.7K $
20TRAWS PHARMA INC 15,07827.6K $